Kuehn Law is investigating Corcept Therapeutics for allegedly failing to disclose FDA concerns about the clinical development of relacorilant, a drug candidate for Cushing's syndrome. The lawsuit claims Corcept misled shareholders by promoting expected FDA approval while hiding risks of rejection. This could impact shareholder value and legal action is urged for those who bought shares before October 31, 2024. The case highlights the importance of transparency in drug approval processes and investor protection.
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
17 Education & Technology Group Inc. reported a strong first quarter for 2026 with net revenues soaring 359% year-over-year to RMB99.5 million, driven by its AI-powered personalized learning app Yiqi Aixue. The company improved its gross margin to 61...
The Schall Law Firm is investigating Simulations Plus, Inc. for potentially issuing false or misleading statements and failing to disclose important information to investors. This probe could impact shareholders who may have suffered losses due to th...
Michael Saylor, Executive Chairman of Strategy, explained that bitcoin's most significant role is not just as a payment method but as the foundation for global money, credit, and capital markets. He envisions BTC-backed financial products offering yi...
SOPHiA GENETICS announced the pricing of its public offering of 10,526,000 ordinary shares at $4.75 per share, raising approximately $50 million before expenses. The company also granted underwriters a 30-day option to buy an additional 1,578,900 sha...
